The US Food and Drug Administration (FDA) has cleared Genentech’s Lucentis 0.3mg (ranibizumab injection), a recombinant humanised monoclonal antibody fragment (lacking an Fc region) designed to treat diabetic macular edema (DME).

The approval of Lucentis in DME was based on Genentech’s parallel, double-masked, three-year Phase III RIDE and RISE trials, which were sham-treatment controlled for 24 months.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A total of 759 patients were randomised into three groups to receive monthly treatment with 0.3mg Lucentis (n=250), 0.5mg Lucentis (n=252) or sham injection (control group, n=257).

Lucentis 0.5mg once monthly was approved by the FDA for treatment of wet age-related macular degeneration (AMD) in 2006 and for macular edema following retinal vein occlusion (RVO) in 2010, according to the company.

The results demonstrated that patients who received 0.3mg Lucentis experienced significant, early (day seven) and sustained (24 months) improvements in vision.

See Also:

A total of 759 patients were randomised into three groups to receive monthly treatment with 0.3mg Lucentis, 0.5mg Lucentis or sham injection.

Vision improvements observed in patients treated with Lucentis at 24 months were maintained with continued treatment through 36 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pooled safety analysis of RIDE and RISE at 24 months showed that the ocular safety of Lucentis in patients with DME was generally consistent with that established in patients with wet AMD and RVO (through 36 months).

The rate of arteriothromboembolic events at 36 months was 10.8% for patients in the 0.3mg treatment group (control period ended at 24 months), while the rate of stroke in DME patients at 24 months was 1.2%, 0.3mg versus 1.6%, control. At 36 months the rate of stroke was 2% for this treatment group.

Genentech chief medical officer and global product development head Hal Barron said, "We developed Lucentis to treat diseases of the eye and are pleased to have received this third US indication to help a new population of people whose eyesight may be affected by diabetes."